Introduction
============

In response to pressure overload, the heart originally undergoes adaptive morphological changes that lead to compensated hypertrophy to maintain the cardiac output. However, prolonged cardiac hypertrophy under consistent stress irreversibly results in cardiac decompensation, which is one of the major risk factors for lethal cardiovascular events by inducing arrhythmias, heart failure, and sudden cardiac death [@B1]. The study on the molecular mechanisms of cardiac hypertrophy and its transition to heart failure is critical in this field in order to develop more specific interventions to prevent or delay this process.

Recent studies suggest that autophagy might be involved in the development of cardiac hypertrophy [@B2],[@B3],[@B4]. Autophagy is an evolutionary conserved cellular process for the degradation and recycling of long-lived protein aggregates and organelles, by forming double membranous vesicles named autophagosomes [@B5], [@B6]. As a regulator of cell death, autophagy is motivated by a series of pathological stimuli, such as pathogen infections, starvation, endoplasmic reticulum (ER) stress, hypoxia, and ischemia [@B7], [@B8]. The abnormality of cardiac autophagy has been found in a variety of cardiovascular diseases including pressure overload-induced cardiac hypertrophy and heart failure [@B2],[@B3],[@B4]. However, how autophagy is involved in the cardiac hypertrophy and heart failure is unclear yet.

Protein kinase D (PKD) is a novel family of serine/threonine kinases and diacylglycerol receptors that belongs to the calcium/calmodulin-dependent kinase superfamily [@B9]. The PKD family includes three members, PKD1, PKD2 and PKD3, with different structural features and enzymological properties. It has been shown that PKD1, the most comprehensive member of this family, is involved in multiple biological processes, such as cell adhesion, migration, survival, proliferation, differentiation and apoptosis. Growing evidence shows that PKD plays an important role in the cardiovascular system, especially in the regulation of myocardial contraction and hypertrophy [@B10].

The protein kinase B (Akt)/mammalian target of rapamycin (mTOR) pathway is a well-known pathway involved in the negative regulation of autophagy in mammal cells [@B11]. The inhibition of mTOR prevents cardiac hypertrophy, suggesting that mTOR and its downstream molecules might be involved in the development of cardiac hypertrophy through the inhibition of autophagy [@B12]. In this study, we demonstrated that PKD is involved in cardiac hypertrophy by regulating autophagy via Akt/mTOR pathway in transverse aortic constriction (TAC)-induced cardiac hypertrophy mouse model using siRNA knockdown and other physiological and molecular techniques.

Materials and methods
=====================

Animals
-------

C57BL/6 male mice at 8-10 weeks old (22-25 g of body weight) were provided by the Animal Center of Beijing Biological Technology, Inc. (Production batch number 20141008). All mice used in this study were housed in a facility with a 12-hour light/dark cycle and constant temperature and humidity. All procedures were in compliance with the Guide for the Care and Use of Laboratory Animals, published by the National Institutes of Health, and were reviewed and approved by the Institutional Animal Research Committee of Shandong University.

Reagents
--------

The following reagents were used in this study and the purchase information was included: Dimethyl sulfoxide (DMSO) from Sigma-Aldrich Co. (St. Louis, MO, USA); Lentiviral PKD siRNA from Genechem Co. (Shanghai, China) with the sequences: TTC AGC TTT AAC TCC CGT T; The autophagy inducer rapamycin from Santa Cruz Biotechnology Inc. (Dallas, TX, USA); The autophagy inhibitor 3-methyladenine (3-MA) from Sigma-Aldrich Co. (St. Louis, MO, USA).

Transverse aortic constriction surgery
--------------------------------------

The mice were randomly assigned to have sham and TAC surgery, which were performed under the anesthesia with 1% isoflurane in oxygen as described previously [@B13]. In brief, the chest was opened at the 2-3 intercostal space along the midsternal line, the aorta was isolated and a 6-0 silk tie was applied against a 27-gauge needle between the innominate and left carotid artery. The needle was removed after ligation and the chest and overlying skin were closed [@B13].

Treatments
----------

As shown in Figure [1](#F1){ref-type="fig"}A, TAC mice were divided into five groups receiving the treatments of vehicle (DMSO), siRNA negative control (NC siRNA), rapamycin, PKD siRNA, and PKD siRNA-3MA, respectively. PKD siRNA at 2×10^8^ transducing units/0.1 ml, the dose that was suggested by the provider (Genechem Co., China), was injected into the tail vein of mice in one day after surgery, and repeated in 2 weeks after surgery (total twice of injection). The autophagy inducer rapamycin (1 mg/kg/day) [@B14] or autophagy inhibitor 3-methyladenine (3-MA, 20 mg/kg/day) [@B15] was administered to mice via intraperitoneal injection daily for 4 weeks starting 1 day after TAC surgery. The doses of rapamycin and 3-MA were used according to previous publications [@B14],[@B15]. Sham mice were also injected with vehicle (DMSO) as control. At the end of experiment, following echocardiographic evaluation, animals were euthanized and tissues were collected for western blot, and histological analyses.

Echocardiography and blood pressure measurement
-----------------------------------------------

A Vevo 770 imaging system equipped with a 30 MHz high frequency scan head (Vevo770®, VisualSonics, Toronto, Canada) was used for echocardiography analysis according to the American Society for Echocardiography leading-edge method [@B16]. Mice were anesthetized with an isoflurane (2%) and O~2~ (1.5L/min) mixture and positioned on a heated pad in a recumbent position. The end-diastolic interventricular septum thickness (IVSd), end-diastolic left ventricular (LV) posterior wall thickness (LVPWd), LV anterior wall thickness (LVAWd), LV end systolic diameter (LVSD), and end-systolic interventricular septum thickness (IVSs) were measured using M-mode. Ejection fraction (EF, %) and fractional shortening (FS, %) were calculated as described previously [@B17]. Systolic blood pressure (SBP) was measured noninvasively using a volume-pressure recording tail-cuff method on conscious, restrained mice using the CODA 6 system (Kent Scientific Corp, Torrington, USA).

Histological and immunohistochemistry study
-------------------------------------------

Histological and immunohistochemistry study were performed as we previously reported [@B18]. LV specimens were fixed in 4% paraformaldehyde and embedded into paraffin blocks. 5 µm sections were cut and stained with hematoxylin and eosin (H&E) to determine the myocyte cross-sectional area (CSA). At least one hundred myocytes in each left ventricle sample were outlined and CSA was evaluated using Image Pro-Plus version 6.0 image analysis software (Media Cybernetics Inc., Rockville, MD, USA) following its instructions. Masson staining was performed to determine collagen deposition as we previously described [@B18]. The slides were examined microscopically and the fibrotic area was determined by the area of myocardial collagen/the area of the field using Image Pro-Plus version 6.0 image analysis software. The average from 10 sections per heart was used for statistical analysis.

Real-time quantitative PCR (RT-qPCR)
------------------------------------

RT-qPCR was used to measure mRNA levels of biomarkers of cardiac hypertrophy, atrial natriuretic factor (ANF) and brain natriuretic peptide (BNP), in the hearts using a SYBR Green PCR kit (Qiagen Inc., Valencia, California, USA), as we previously described [@B19]. The following primers were used for real-time PCR: 5\'-GGA AAA GGC AGT CGA TTC TG-3\' and 5\'-CAG AGT GGG AGA GGC AAG AC-3\' for ANF; 5\'-GCC AGT CTC CAG AGC AAT TC-3\' and 5\'-TCT TTT GTG AGG CCT TGG TC-3\' for BNP; 5\'-AGA ACA TCA TCC CTG CAT CC-3\' and 5\'-CAC ATT GGG GGT AGG AAC AC-3\' for GAPDH. Amplification and detection were performed with the ABI7500 Sequence Detection System (Applied Biosystems, Foster City, CA). A crossing threshold (CT) value was obtained, corresponding to the fractional number of amplification cycles where the PCR curve reaches a program-defined threshold amount of fluorescence. Relative quantification of RT-qPCR data was performed using the delta CT (sample CT minus GAPDH CT) and delta delta CT (sample delta CT minus comparator delta CT) methods according to previously described [@B20]. Expression levels are reported relative to the geometric mean of the control group.

Transmission electron microscopy analysis
-----------------------------------------

LVs were cut into 1 mm^3^ cubes, fixed with 2% glutaraldehyde in PBS at 4°C overnight. The fixed samples were then post-fixed with 1% buffered osmium tetroxide, embedded, and analyzed using transmission electron microscopy (JEM-1200EX, Japan) as described previously [@B18].

Western blot analysis
---------------------

Western blot analysis was performed as previously described [@B18]. Proteins were separated by electrophoresis through an 8%-12% SDS-polyacrylamide gel, and transferred to polyvinylidene difluoride membranes. The membranes were probed with antibodies against LC3B (1:1000 dilution), Beclin 1 (1:1000 dilution), SQSTM1/p62 (1:1000 dilution), total AMPK and phosphorylated AMPK (1:2000 dilution), total Akt and phosphorylated Akt (Ser473) (1:1000 dilution), total and phosphorylated mTORSer2448 (1:1000 dilution), total and phosphorylated S6K (Ser235/236) (1:1000 dilution), total and phosphorylated PKD (Ser2486, 1:1000 dilution), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH; 1:5000) was used as a loading control. All the antibodies were purchased from Cell Signaling Technology, Inc. (Danvers, MA, USA). The bands were digitized using MCID image analysis software (Imaging Research, Inc., Ontario, Canada). Each band was expressed in arbitrary units and normalized to GAPDH.

Statistics
----------

The statistical analysis was performed using the SPSS (Statistical Package for the Social Sciences) software package, version 16.0 (SPSS Inc, Chicago, IL, USA). The results are expressed as the mean±SEM. All statistical significance was determined by one-way ANOVA, followed by Tukey post-hoc tests. A value of *P*\<0.05 was considered statistically significant.

Results
=======

TAC-induced cardiac structural and functional changes
-----------------------------------------------------

At four weeks after TAC surgery, rapamycin, PKD siRNA, or 3-MA treatments did affect systolic blood pressure (data not shown). While there were no differences of body weight among groups (data not shown), the heart size, both whole heart weight and left ventricle weight increased in TAC mice compared to sham animals, which were decreased by rapamycin or PKD siRNA treatment. The treatment with 3-MA, an autophagy inhibitor, inhibited the effects of PKD siRNA on TAC-induced heart and LV weights (Figure [1](#F1){ref-type="fig"}A-C).

Consistent with the findings from heart size and weights, echocardiographic study showed that hypertrophic indicators including LVPWd, LVAWd, LVSd, IVSd, and IVSs significantly increased in the TAC vs. sham mice (*P*\<0.05, Table [1](#T1){ref-type="table"}), which were attenuated by the treatments of rapamycin and PKD siRNA. Moreover, the treatment with 3-MA inhibited the effects of PKD siRNA on TAC-induced cardiac hypertrophy (Table [1](#T1){ref-type="table"}, Figure [1](#F1){ref-type="fig"}D). The systolic function reflected by EF and FS significantly impaired by TAC surgery, which were improved with rapamycin or PKD siRNA treatment. Also, 3-MA inhibited the cardioprotective effects of PKD siRNA (Table [1](#T1){ref-type="table"}).

The TAC-induced cardiac hypertrophy was confirmed by the hematoxylin and eosin (HE) staining in left ventricles showing that the cardiomyocytes in TAC mice were significantly larger than that in sham mice, which were attenuated by rapamycin or PKD siRNA treatment. Similarly, to echocardiographic findings, 3-MA inhibited the effects of PKD siRNA on cardiomyocyte size (Figure [2](#F2){ref-type="fig"}A,2B). These results are consistent with the gene expression changes of biomarkers for cardiac hypertrophy, ANF and BNP (Figure [2](#F2){ref-type="fig"}C,2D).

Masson\'s trichrome staining showed a dramatically elevated collagen in the heart of TAC mice as compared with the control group. The collagen volume fraction was reduced by rapamycin or PKD siRNA versus vehicle or control siRNA treatment. Again, the cardiac collagen reduction by PKD siRNA was inhibited by co-treatment with 3-MA (Figure [3](#F3){ref-type="fig"}).

Cardiac autophagy in TAC-induced cardiac hypertrophy
----------------------------------------------------

To determine the autophagic activity and the effects of PKD deletion in pressure overload-induced cardiac hypertrophy, we assessed the expression of autophagosome markers, light chain 3B (LC3B; including LC3-I and LC3-II), beclin-1 and p62, which are key proteins involved in the regulation of autophagy. As shown in Figure [4](#F4){ref-type="fig"}, results from Western blot demonstrated that LC3-II/LC3-I ratio significantly increased after pressure overload, while it was further increased by rapamycin or PKD knockdown. Compared with sham animals, TAC mice treated with control siRNA significantly increased while TAC mice treated with vehicle tended to increase cardiac Beclin 1 expression. Similarly to LC3-II/ LC3-I ratio changes, both rapamycin and PKD siRNA increased Beclin 1 expression. 3MA treatment inhibited PKD siRNA-induced increases of LC3-II/ LC3-I ratio and Beclin 1 expression. In comparison to sham mice, cardiac p62 expression did not change in TAC mice treated with vehicle or control siRNA. However, both rapamycin and PKD siRNA decreased p62 expression, which was inhibited by 3MA treatment (Figure [4](#F4){ref-type="fig"}).

Electron microscopic examination revealed that both autophagic vacuoles and lysosomes were abundant within cardiomyocytes in the TAC-induced hypertrophic hearts when compared with sham mice, and this electron-microscopic portrayal of autophagy was even more exaggerated in TAC mice treated with either rapamycin or PKD siRNA, while the effect of PKD siRNA was inhibited by 3MA treatment (Figure [5](#F5){ref-type="fig"}). Fragmented mitochondria with extensive swelling and remodeling have been shown in TAC-induced hypertrophic heart. PKD siRNA treatment attenuated the disorganized sarcomere structure and mitochondrial disarray in the hypertrophic heart, accompanied with increased autophagosomes (Figure [5](#F5){ref-type="fig"}).

PKD knockdown inhibited TAC-induced the activation of Akt/mTOR/S6k pathway
--------------------------------------------------------------------------

Western blot showed that the phosphorylated Akt, mTOR and S6K significantly increased in the heart of TAC mice compared to sham animals. These increases were inhibited by either rapamycin or PKD siRNA treatment. However, the inhibitory effects of PKD siRNA on the phosphorylation of Akt and mTOR were blocked by co-treatment with 3MA (Figure [6](#F6){ref-type="fig"}). Cardiac AMPK phosphorylation tended to increase in TAC mice. Rapamycin or PKD siRNA did not affect AMPK phosphorylation in the heart. Pressure overload by TAC increased cardiac PKD phosphorylation in comparison to sham mice. As expected, PKD siRNA decreased PKD expression \~80% in the heart (Figure [6](#F6){ref-type="fig"}A).

Discussion
==========

This study demonstrates that the PKD knockdown by siRNA prevents cardiac hypertrophy and remodeling in TAC mice model. The cardioprotective effects of PKD knockdown might be through the suppression of the Akt/mTOR pathways and the subsequent enhancement of cardiac autophagy. These findings provide a new insight into the mechanisms of PKD, cardiac autophagy and cardiac hypertrophy.

Accumulating evidence demonstrates that PKD plays an important role in the cardiovascular system, particularly in the regulation of myocardial contraction, and is involved in cardiac hypertrophy and remodeling [@B21]. A significant increase of PKD expression and activity has been reported in the hypertrophic heart of spontaneously hypertensive rats, and TAC-induced cardiac hypertrophy [@B18],[@B22],[@B23]. However, the exact mechanisms how PKD be involved in the cardiac hypertrophy are still unclear. In the present study, the molecular roles of PKD in cardiac hypertrophy were determined using the technique of siRNA-mediated gene knockdown in TAC mouse model, which is a widely used animal model for the basic research of pressure overload-induced cardiac hypertrophy. TAC surgery with a 27-gauge needle successfully induced cardiac hypertrophy evidenced by the echocardiography and immunohistochemistry study showing the increased wall thickness and cross-sectional cardiomyocyte area in four weeks after TAC. We demonstrated that PKD is activated in TAC mice compared to sham group. Most importantly, PKD knockdown with siRNA attenuated cardiac hypertrophy and remodeling in response to pressure overload. This result further demonstrates that the activated PKD is one of the mechanisms of pressure overload-induced cardiac hypertrophy.

Autophagy in cardiomyocytes has been shown to play an important role in the reaction of cardiomyocytes to numerous types of stress, and is crucial in the maintenance of cardiac function [@B2],[@B3],[@B4],[@B24]. A number of studies indicate that the induction of autophagic activity protects heart through the elimination of injured organelles and proteins. It is reported that activating autophagy may attenuate pressure overload-induced cardiac hypertrophy [@B25], while the inhibition of autophagy induces cardiac hypertrophy and diastolic dysfunction with aging [@B26],[@B27]. However, excessive autophagy could cause cell death and ultimately lead to the function impairment [@B28],[@B29]. Recent studies revealed the significantly increased autophagy in the failing hearts, including dilated cardiomyopathy, valvular heart disease, hypertensive heart disease and chronic ischemia [@B18],[@B30]. However, the exact roles of autophagy in cardiac hypertrophy and its transition to heart failure are not clear. Timing appears to be the key for the different roles of autophagy at various stages of cardiac hypertrophy and heart failure. In the present study, the autophagy significantly increased in the heart of TAC compared with sham mice. The inhibitor of mTOR, rapamycin, which is a typical autophagy inducer, prevents cardiac hypertrophy and remodeling, and improves heart function, accompanied by activation of autophagy in this TAC-induced cardiac hypertrophic mouse model. These results demonstrate that the activated autophagy has protective effects during the pathogenesis of pressure overload-induced cardiac hypertrophy and its transition to heart failure in this TAC mouse model.

One of the main findings in this study is that PKD knockdown attenuates TAC-induced cardiac hypertrophy and remodeling accompanied by increased cardiac autophagy. Moreover, the PKD knockdown-induced activated cardiac autophagy and the attenuation of cardiac hypertrophy were inhibited by 3-MA, an autophagy inhibitor, suggesting that PKD knockdown ameliorated cardiac hypertrophy and remolding through its inductive effects of autophagy.

mTOR is believed to be an important negative regulator of autophagy [@B31]; direct inhibition of mTOR is sufficient to trigger autophagy induction. mTOR pathway has also been shown to have a key regulatory function in cardiac hypertrophy [@B3],[@B4],[@B32]. mTOR is regulated by and communicates with multiple signaling pathways such as activated by Akt (protein kinase B, PKB). Sustained Akt activation induces cardiac hypertrophy, which may be through its regulation on mTOR pathway. AMP-activated protein kinase (AMPK) induces autophagy through its downstream target phosphorylation of mTOR [@B33], which might be one of the mechanisms of the favorable effects of AMPK in inhibiting cardiac hypertrophy [@B34].

In this study, we found that PKD knockdown significantly downregulated p-Akt, p-S6K, and p-mTOR in the hypertrophic hearts of TAC mice. To confirm whether PKD knockdown promotes autophagy through mTOR pathway, 3-MA was used in this study, which is demonstrated to inhibit autophagy by blocking autophagosome formation via the inhibition of phosphatidylinositol 3-kinases (PI3K). 3-MA increased the phosphorylation of Akt, s6k and mTOR, and inhibited PKD knockdown-induced autophagy, suggesting Akt/mTOR pathway was a pivotal mechanism by which PKD is involved in regulation of cardiac autophagy and hypertrophy. On the other hand, the AMPK, which is an upstream signal of mTOR, was not altered after PKD siRNA treatment, indicating that mTOR does not play a role in AMPK-induced autophagy in hearts.

Limitations and future studies
==============================

We also realized the limitations of this study. First, this study focused on the PKD knockdown-induced autophagy change in cardiomyocytes. However, the abnormality of autophagy in non-cardiomyocytes, especially in cardiac fibroblasts, might be also involved in the development of cardiac hypertrophy. The activation of autophagy in cardiac fibroblasts attenuates angiotensin II or adrenergic stimulation-induced cardiac fibrosis and remodeling [@B35],[@B36]. In this study, we found that PKD siRNA attenuated TAC-induced cardiac fibrosis. The effects of PKD knockdown on cardiac fibrosis might be also through its regulation on autophagy in cardiac fibroblasts, which needs further studies to prove. Second, besides Akt/mTor pathway, cardiac autophagy was also regulated by other signaling pathways such as MEK/ERK/Beclin-1 pathway [@B37]. It would be of great interest to compare and investigate the interactions of these pathways mediating cardiac autophagy activation. Another limitation of this study is that only one time point was studied for cardiac autophagy and hypertrophy. Actually, cardiac autophagy might play different roles at various stages during the progression of cardiac hypertrophy and heart failure. Future studies are needed to determine that, at a series of time points, the different functional roles of cardiac autophagy in the development of cardiac hypertrophy and heart failure.

In summary, to our knowledge, this study provides the first evidence that PKD knockdown attenuates pressure overload-induced cardiac hypertrophy and remodeling through inducing autophagy via the inhibition of Akt/mTOR pathway. These results indicate that PKD might be a potential target gene for future therapeutic strategy of cardiac hypertrophy.
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![**TAC-induced cardiac hypertrophy with various treatments.** (A) Timeline of study protocol. (B) Representative gross heart pictures. (C) Heart weight/body weight (HW/BW) and (D) left ventricle weight/body weight (LVW/BW) ratios. (E) Representative M-mode echocardiographic images after 4 weeks of TAC. TAC, transverse aorta constriction; V, vehicle; NC, negative control; Rap, rapamycin. Data are mean±SEM, n=8-9/group. \* *P*\<0.05 vs. sham; \# *P*\<0.05 vs. vehicle or NC siRNA treated TAC mice; ... *P*\<0.05 vs. TAC-PKD siRNA.](ijbsv13p0276g001){#F1}

![**H&E staining of left ventricles and real-time PCR.** (A) Representative images of H&E staining in left ventricle transverse sections. (B) Quantification results of myocyte cross-sectional areas (CSA). (C) ANF mRNA level in the heart. (D) BNP mRNA level in the heart. TAC, transverse aorta constriction; V, vehicle; NC, negative control; Rap, rapamycin. Data are mean±SEM, n=8-9/group. \* *P*\<0.05 vs. sham; \# *P*\<0.05 vs. vehicle or NC siRNA treated TAC mice; ... *P*\<0.05 vs. TAC-PKD siRNA.](ijbsv13p0276g002){#F2}

![**Fibrosis in left ventricles.** (A) Representative images of Masson\'s Trichrome staining in left ventricles, the blue stands for fibrosis. (B) Quantification results of the cardiac fibrosis area. TAC, transverse aorta constriction; V, vehicle; NC, negative control; Rap, rapamycin. Data are mean±SEM, n=8-9/group. \* *P*\<0.05 vs. sham; \# *P*\<0.05 vs. vehicle or NC siRNA treated TAC mice; ... *P*\<0.05 vs. TAC-PKD siRNA.](ijbsv13p0276g003){#F3}

![**Biomarkers of cardiac autophagy.** (A) Representative images of Western blot for LC3, Beclin 1, and p62. (B) Quantification of the signal densities from Western blot. TAC, transverse aorta constriction; V, vehicle; NC, negative control; Rap, rapamycin. Data are mean±SEM, n=8-9/group. \* *P*\<0.05 vs. sham; \# *P*\<0.05 vs. vehicle or NC siRNA treated TAC mice; ... *P*\<0.05 vs. TAC-PKD siRNA.](ijbsv13p0276g004){#F4}

![**Autophagic vacuoles in cardiomyocytes.** (A) Representative electron micrographs showing autophagic vacuoles in cardiomyocytes of TAC mice with various treatments (magnification: x10,000). Arrows indicate autophagic vacuoles. (B) Quantification of the number of autophagosomes/cell in different groups (a random number of 30 cells were selected for each group). TAC, transverse aorta constriction; V, vehicle; NC, negative control; Rap, rapamycin. Data are mean±SEM, n=8-9/group. \* *P*\<0.05 vs. sham; \# *P*\<0.05 vs. vehicle or NC siRNA treated TAC mice; ... *P*\<0.05 vs. TAC-PKD siRNA.](ijbsv13p0276g005){#F5}

![**Signaling pathways regulating cardiac autophagy.** (A) Representative images of Western blot for phosphorylated and total Akt, mTOR, S6K, AMPK, and PKD in the theart. (B) Quantification of the signal densities from Western blot. TAC, transverse aorta constriction; V, vehicle; NC, negative control; Rap, rapamycin. Data are mean±SEM, n=8-9/group. \* *P*\<0.05 vs. sham; \# *P*\<0.05 vs. vehicle or NC siRNA treated TAC mice; ... *P*\<0.05 vs. TAC-PKD siRNA.](ijbsv13p0276g006){#F6}

###### 

Echocardiographic analysis of left ventricles.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Group               IVSd\               IVSs\               LVSd\               LVIDs\              LVAWd\              LVPWd\              EF\                 FS\
                      (mm)                (mm)                (mm)                (mm)                (mm)                (mm)                (%)                 (%)
  ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- -------------------
  Sham-V              0.16±0.02           0.25±0.02           0.70±0.02           2.25±0.07           1.24±0.06           0.67±0.02           72.5±0.02           33.8±0.32

  TAC-V               0.21±0.02\*         0.31±0.03\*         0.90±0.02\*         2.51±0.02\*         1.78±0.03\*         0.82±0.05\*         58.0±0.01\*         26.6±0.68\*

  TAC-NC siRNA        0.20±0.02\*         0.30±0.02\*         0.89±0.01\*         2.50±0.08           1.76±0.05\*         0.80±0.02\*         60.2±0.02\*         27.6±0.02\*

  TAC-rapamycin       0.18±0.02**^\#^**   0.27±0.02**^\#^**   0.78±0.01**^\#^**   2.27±0.04**^\#^**   1.43±0.02**^\#^**   0.74±0.03**^\#^**   66.3±0.01**^\#^**   32.6±0.34**^\#^**

  TAC-PKD siRNA       0.17±0.02**^\#^**   0.29±0.03           0.76±0.02           2.29±0.06**^\#^**   1.48±0.03**^\#^**   0.77±0.05           67.8±0.01**^\#^**   33.6±0.26**^\#^**

  TAC-PKD siRNA-3MA   0.20±0.02^...^      0.28±0.03           0.85±0.02^...^      2.46±0.03^...^      1.69±0.07^...^      0.79±0.02           61.4±0.04^...^      29.8±0.12^...^
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

IVSd, interventricular septum thickness in diastole; IVSs, interventricular septum end-systolic thickness; LVSd, left ventricle (LV) end systolic diameter; LVIDs, LV internal dimension in systole; LVAWd, LV anterior wall thickness at diastole; LVPWd, LV posterior wall thickness at diastole; EF, ejection fraction; FS, fractional shortening; TAC, transverse aortic constriction; V, vehicle; NC, negative control. Data are mean±SEM, n=8-9/group. \* *P*\<0.05 vs. sham; \# *P*\<0.05 vs. vehicle or NC siRNA treated TAC mice; ... *P*\<0.05 vs. TAC-PKD siRNA.
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